Article info
Clinical trial
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
- Correspondence to Dr Jyoti Mayadev, University of California San Diego, La Jolla, California 92093-0021, USA; jmayadev{at}ucsd.edu
Citation
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Publication history
- Accepted December 3, 2019
- First published December 22, 2019.
Online issue publication
September 22, 2020
Article Versions
- Previous version (22 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.